China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio’s innovative Synova platform.
Synova Platform and Research Focus
The Synova platform is an intelligent and high-throughput macrocyclic peptide drug research and development platform. It is designed to support research programs exploring future treatments for chronic diseases, including rare, autoimmune, and metabolic conditions. This platform represents a significant advancement in the discovery and optimization of macrocyclic peptide therapeutics.
Financial Terms and Milestones
Under the deal terms, AstraZeneca will provide upfront payments and potential near-term milestone payments totaling USD 75 million. The agreement also includes up to USD 3.4 billion in additional development and commercial milestones, along with tiered royalties based on global sales. This substantial financial commitment reflects the potential of the collaboration to yield novel treatments for unmet medical needs.
Expansion of R&D Capabilities
Furthermore, AstraZeneca will make an equity investment in Syneron Bio, which expects to expand its Beijing R&D center through this collaboration. This expansion will enhance Syneron Bio’s research capabilities and accelerate the development of innovative therapies for chronic diseases.-Fineline Info & Tech
Leave a Reply